-
NMPA Issues the Announcement on 6 Technical Review Guidances for Registration Including the Technical Review Guidance for the Registration of Disposable Breast localization Wire
2020-07-09
To strengthen the supervision and guidance over medical device registration, and further improve the quality of registration review, NMPA has organized to formulate 6 technical review guidances for registration including the Technical Review Guidance for the Registration of Disposable Breast localization Wire.
-
NMPA Issues the Notice on Matters Related to Further Strengthening Management for Mandatory Industry Standards of Medical Devices
2020-07-09
NMPA issued the notice on matters related to further strengthening management for mandatory industry standards of medical devices.
-
NMPA Issues the Announcement on Three Documents Including the Working Procedures for Review of Breakthrough Therapy Drugs (Interim)
2020-07-07
NMPA has organized to formulate the Working Procedures for Review of Breakthrough Therapy Drugs (Interim), Working Procedures for Review and Approval of Applications for Conditional Approval of Drug Marketing (Interim) and Working Procedures for Priority Review and Approval of Drug Marketing Authorization (Interim).
-
NMPA Issues the Announcement on Implementing the 2020 Edition of the Pharmacopoeia of the People's Republic of China
2020-07-03
The 2020 Edition of the Pharmacopoeia of the People's Republic of China (hereinafter referred to as 2020 Chinese Pharmacopoeia) has been issued by NMPA and NHC Announcement.
-
Announcement of National Medical Products Administration and National Health Commission on Issuing the 2020 Edition of the Pharmacopoeia of the People's Republic of China
2020-07-02
On July 2, 2020, National Medical Products Administration and National Health Commission issued an announcement on the 2020 Edition of the Pharmacopoeia of the People's Republic of China.
-
NMPA Issues the Revised Draft of the Blood Products Appendix in the Good Manufacturing Practice for Drugs (2010 Revision)
2020-07-02
NMPA has revised the Blood Products Appendix. The Appendix was issued as a supporting document for the Good Manufacturing Practice for Drugs (2010 Revision) on July 2, 2020, and shall come into force as of October 1, 2020.